However, our previous study used WGCNA analysis, combined with a survival analysis curve and the GEPIA database for validation, and discovered that FAM110B was linked to a good survival time for patients with pancreatic cancer (Li et al., 2023), which was consistent with the results of Xi and Zhang (2018). Here, FAM110B is linked to familial pancreatic carcinoma.